Status:

COMPLETED

Reducing Anemia in Pregnancy in India: the RAPIDIRON Trial

Lead Sponsor:

Thomas Jefferson University

Collaborating Sponsors:

Children's Investment Fund Foundation

Jawaharlal Nehru Medical College

Conditions:

Iron Deficiency Anemia

Infant, Low Birth Weight

Eligibility:

FEMALE

18-40 years

Phase:

PHASE4

Brief Summary

Anemia is a worldwide problem with iron deficiency being the most common cause. When anemia occurs in pregnancy, it increases the risk of adverse maternal, fetal, and postnatal outcomes. Anemia rates ...

Detailed Description

Anemia is a worldwide problem with iron deficiency being the most common cause. When occurring in pregnancy, anemia increases the risk of adverse maternal, fetal and neonatal outcomes, including mater...

Eligibility Criteria

Inclusion

  • Inclusion Criteria for Study Consent for Initial Participation:
  • Pregnant women between 18-40 years of age at time of consent that received education about the study and were capable of giving informed consent;
  • Hemoglobin concentration of 7 - 10.4 g/dL;
  • Expressed intent and expectation of remaining in the designated research area during pregnancy and delivering in a facility in or near the research area and remaining in the area to enable study participant and data collection consistent with the research protocol;
  • Expressed willingness that specifically includes agreement to randomization to the standard care study arm (of oral iron) or to one of the two arms involving treatment with single-dose IV iron.
  • Additional Inclusion Criteria for Randomization and Continued Study Participation:
  • Iron deficiency anemia, defined for this study as moderate anemia with hemoglobin concentration level between 7 - 9.9 g/dL, serum transferrin saturation (TSAT) \<20%, and/or ferritin \<30 ng/mL;
  • Presence of a live, singleton, intrauterine fetus and dating ultrasound (at visit #2) that indicates a pregnancy that, at randomization, would be between the beginning of week 14 and prior to 17 weeks 0 days.
  • Exclusion Criteria:
  • Fetal anomaly, if detectable when an initial ultrasound is done to date the pregnancy (subsequent discovery of a fetal anomaly is not viewed as an exclusion criterion);
  • History of cardiovascular disease, hemoglobinopathy, or other disease or condition considered a contraindication for treatment, including conditions recommended for exclusion by the manufacturers of oral or IV iron to be used in this study;
  • Any condition that, in the opinion of the consenting physician, warrants study exclusion.

Exclusion

    Key Trial Info

    Start Date :

    March 15 2021

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    January 21 2024

    Estimated Enrollment :

    4368 Patients enrolled

    Trial Details

    Trial ID

    NCT05358509

    Start Date

    March 15 2021

    End Date

    January 21 2024

    Last Update

    May 24 2024

    Active Locations (4)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (4 locations)

    1

    S. Nijalingappa Medical College

    Bagalkot, Karnataka, India

    2

    Jawaharlal Nehru Medical College

    Belagavi, Karnataka, India

    3

    Raichur Institute of Medical Sciences

    Rāichūr, Karnataka, India

    4

    Sawai Man Singh Medical College

    Jaipur, Rajasthan, India